1200024000132002640013200264001440028800
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)

1200024000132002640013200264001440028800
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)
The development of multiple myeloma MM is accompanied by a variety of specific alterations in the number or structure of genes. Gene translocations associated with immunoglobulin heavy chain (IGH) occur in 50% to 60% of MM and are associated with a number of non-random specific translocations, such as t(4; 14) (p16.3; q32) (FGFR3/IGH fusion), t(11; 14) (q13; q32) (CCND1/IGH fusion), t(14; 16) (q32; q23) (MAF/IGH fusion) and t(14; 20) (MAFB/IGH fusion);
These fusion genes can be used for further typing to determine prognosis and therapeutic treatment after a positive initial screening for IGH breaks in multiple myeloma.